USD 58.42 BN

MARKET SIZE, 2031

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

4

4.3

UNMET NEEDS AND WHITE SPACES

4.4

INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES

4.5

STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5

5.1

PORTER’S FIVE FORCES ANALYSIS

5.1.1

THREAT OF NEW ENTRANTS

5.1.2

THREAT OF SUBSTITUTES

5.1.3

BARGAINING POWER OF SUPPLIERS

5.1.4

BARGAINING POWER OF BUYERS

5.1.5

INTENSITY OF COMPETITION RIVALRY

5.2

MACROECONOMIC OUTLOOK

5.2.1

GDP TRENDS AND FORECAST

5.2.2

TRENDS IN THE CELL CULTURE MARKET

5.2.3

TRENDS IN HEALTHCARE/PHARMA INDUSTRY

5.4.1

EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS

5.5.1

AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT (2022-2024)

5.5.2

AVERAGE SELLING PRICE TREND, BY COUNTRY (2022-2024)

5.6

TRADE ANALYSIS (2020-2024)

5.7

KEY CONFERENCES AND EVENTS, 2026–2027

5.8

TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

5.9

INVESTMENT AND FUNDING SCENARIO

5.9.1

VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE

5.10

IMPACT OF 2025 US TARIFF– CELL CULTURE MARKET

5.10.3

PRICE IMPACT ANALYSIS

5.10.4

IMPACT ON COUNTRIES/REGIONS

5.10.5

IMPACT ON END-USE INDUSTRIES

6

TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

6.1.1

SINGLE-USE TECHNOLOGY

6.2

COMPLEMENTARY TECHNOLOGIES

6.2.1

HIGH-THROUGHPUT SCREENING

6.3

ADJACENT TECHNOLOGIES

6.3.1

MICROFLUIDICS AND ORGAN-ON-A-CHIP

6.4

TECHNOLOGY/PRODUCT ROADMAP

6.7

IMPACT OF AI/GEN AI ON THE CELL CULTURE MARKET

6.7.1

TOP USE CASES AND MARKET POTENTIAL

6.7.2

CASE STUDIES OF AI IMPLEMENTATION IN THE CELL CULTURE MARKET

6.7.3

INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS

6.7.4

CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN THE CELL CULTURE MARKET

7

SUSTAINABILITY AND REGULATORY LANDSCAPE

7.1

REGIONAL REGULATIONS AND COMPLIANCE

7.1.1

REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

7.2

SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES

7.3

CERTIFICATIONS, LABELING, ECO-STANDARDS

8

CUSTOMER LANDSCAPE & BUYER BEHAVIOR

8.1

DECISION-MAKING PROCESS

8.2

BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA

8.3

ADOPTION BARRIERS & INTERNAL CHALLENGES

8.4

UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9

CELL CULTURE MARKET, BY PRODUCTS, (MARKET SIZE 2023 – 2030, FORECAST TO 2030 – IN VALUE, USD MILLION)

COMPARATIVE ASSESSMENT OF KEY OFFERINGS, THEIR MARKET POTENTIAL, AND REVENUE TRENDS

9.2.1

SERA, MEDIA, AND REAGENTS

9.2.1.1.1

SERUM-FREE MEDIA

9.2.1.1.2

CLASSICAL MEDIA & SALTS

9.2.1.1.3

STEM CELL CULTURE MEDIA

9.2.1.1.4

CHEMICALLY DEFINED MEDIA

9.2.1.1.5

SPECIALTY MEDIA

9.2.1.2.3

BUFFERS & CHEMICALS

9.2.1.2.4

CELL DISSOCIATION REAGENTS

9.2.1.2.5

BALANCED SALT SOLUTIONS

9.2.1.2.9

ATTACHMENT & MATRIX FACTORS

9.2.1.2.7

ANTIBIOTICS/ANTIMYCOTICS

9.2.1.2.8

CRYOPROTECTIVE REAGENTS

9.2.1.2.9

CONTAMINATION DETECTION KITS

9.2.1.2.10

OTHER REAGENTS

9.2.1.3.1

FETAL BOVINE SERA

9.2.1.3.2

ADULT BOVINE SERA

9.2.1.3.3

OTHER ANIMAL SERA

9.2.2.1CELL FACTORY SYSTEMS/CELL STACKS

9.2.2.2

ROLLER/ROUX BOTTLES

9.3.1.1

CONVENTIONAL BIOREACTORS

9.3.1.2

SINGLE-USE BIOREACTORS

9.3.2.1

REFRIGERATORS & FREEZERS

9.3.2.2

CRYOSTORAGE SYSTEMS

9.3.3.1

FILTRATION SYSTEMS

9.3.3.3

CARBON DIOXIDE INCUBATORS

9.3.3.7

BIOSAFETY CABINETS

9.3.3.8

OTHER SUPPORTING EQUIPMENT

10

CELL CULTURE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)

SECTOR-SPECIFIC ADOPTION DRIVERS, DEMAND DYNAMICS AND MARKET POTENTIAL ACROSS EACH APPLICATION

10.2

BIOPHARMACEUTICAL PRODUCTION

10.2.1

MONOCLONAL ANTIBODY PRODUCTION

10.2.2

VACCINE PRODUCTION

10.2.3

OTHER THERAPEUTIC PROTEIN PRODUCTION

10.4

TISSUE ENGINEERING AND REGENERATIVE MEDICINE

10.4.1

CELL & GENE THERAPY

10.4.2

OTHER TISSUE ENGINEERING AND REGENERATIVE MEDICINE APPLICATIONS

10.5

DRUG SCREENING & DEVELOPMENT

11

CELL CULTURE MARKET, BY END USER, 2023-2030 (USD MILLION)

SECTOR-SPECIFIC ADOPTION DRIVERS, DEMAND DYNAMICS AND MARKET POTENTIAL ACROSS EACH END-USE INDUSTRY

11.2

PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

11.3

HOSPITALS AND DIAGNOSTIC LABORATORIES

11.4

RESEARCH & ACADEMIC INSTITUTES

12

CELL CULTURE MARKET, BY REGION, 2023-2030 (USD MILLION)

ASSESSMENT OF GROWTH PATTERNS, INDUSTRY FORCES, REGULATORY LANDSCAPE, AND MARKET POTENTIAL ACROSS KEY REGIONS AND COUNTRIES

12.2.3

MACROECONOMIC OUTLOOK OF NORTH AMERICA

12.3.7

MACROECONOMIC OUTLOOK OF EUROPE

12.4.6

REST OF ASIA PACIFIC

12.4.7

MACROECONOMIC OUTLOOK OF ASIA PACIFIC

12.5.3

REST OF LATIN AMERICA

12.5.4

MACROECONOMIC OUTLOOK OF LATIN AMERICA

12.6.2

REST OF MIDDLE EAST

12.6.3

MACROECONOMIC OUTLOOK OF THE MIDDLE EAST

12.7.1

MACROECONOMIC OUTLOOK OF AFRICA

STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL

13.2

KEY PLAYERS STRATEGY/ RIGHT TO WIN

13.3

REVENUE ANALYSIS, 2022-2024

13.4

MARKET SHARE ANALYSIS,

13.5

COMPANY EVALUATION MATRIX: KEY PLAYERS

13.5.5

COMPANY FOOTPRINT: KEY PLAYERS,

13.5.5.1

COMPANY FOOTPRINT

13.5.5.2

REGION FOOTPRINT

13.5.5.3

PRODUCT FOOTPRINT

13.5.5.4

APPLICATION FOOTPRINT

13.6

COMPANY EVALUATION MATRIX: START-UPS/SMES,

13.6.1

PROGRESSIVE COMPANIES

13.6.2

RESPONSIVE COMPANIES

13.6.5

COMPETITIVE BENCHMARKING: STARTUPS/SMES,

13.6.5.1

DETAILED LIST OF KEY STARTUPS/ SMES

13.6.5.2

COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS

13.8

VALUATION AND FINANCIAL METRICS

13.9

COMPETITIVE SCENARIO

13.9.3

OTHER DEVELOPMENTS

14.1.1THERMO FISHER SCIENTIFIC, INC.

14.1.2

DANAHER CORPORATION

14.1.6

CORNING INCORPORATED

14.1.9

AGILENT TECHNOLOGIES, INC.

14.1.10

FUJIFILM HOLDINGS CORPORATION

15.1.1.1

KEY SOURCES OF SECONDARY DATA

15.1.1.2

KEY OBJECTIVES OF SECONDARY DATA

15.1.2.1

BREAKDOWN OF PRIMARIES

15.1.2.2

KEY OBJECTIVES OF PRIMARY RESEARCH

15.2

MARKET SIZE ESTIMATION

15.2.1

CELL CULTURE MARKET SIZE ESTIMATION

15.2.1.1

COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)

15.2.1.2

MNM REPOSITORY ANALYSIS

15.2.1.3

SECONDARY ANALYSIS

15.2.1.4

PRIMARY RESEARCH

15.2.1.4.1

INSIGHTS FROM PRIMARY EXPERTS

15.2.2

SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)

15.3

MARKET GROWTH RATE PROJECTIONS

15.5

RESEARCH ASSUMPTIONS

15.6

RESEARCH LIMITATIONS AND RISK ASSESSMENT

16.2

KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

16.3

AVAILABLE CUSTOMIZATIONS

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Cell culture refers to the removal of cells from an animal or plant and their subsequent growth in an artificial environment under controlled conditions. It is a process of growing cells outside their natural environment, typically in a laboratory setting. This technique allows researchers to study cells in a controlled environment, providing insights into their behavior, growth, metabolism, and response to various stimuli.

The scope of this report includes products such as equipment and consumables, such as media, sera, reagents, vessels, bioreactors, storage equipment, and other cell culture-supporting equipment that support the cell culture process.

Key Stakeholders

Report Objectives

• Product Matrix, which gives a detailed comparison of the product portfolios of the top five companies.

Regional Analysis

There’s a growing shift toward serum-free, chemically defined media and single use technologies, driven by regulatory pressure, reproducibility issues, risk of contamination and ethical sourcing concerns. Adoption is particularly strong in Europe, where more than 40% of manufacturers reports transitioning to animal-free alternatives.

Continuous biomanufacturing is enabling real-time process monitoring, higher yields, and smaller facility footprints. In upstream cell culture, continuous perfusion systems are gaining traction and can improve productivity by 2–3x compared to traditional fed-batch processes.

Integration of automated culture systems and AI-driven cell monitoring solutions used for media optimization, real-time cell monitoring, and predictive analytics is improving reproducibility and reducing manual error, with up to 30-40% efficiency gains in high-throughput labs.

Cell and gene therapies are transforming the cell culture market landscape, with over 4,400 gene, cell and RNA-based therapies in development globally. This has pushed demand for GMP-grade media, automated systems, and closed bioprocessing platforms.

3D cultures and organoids are gaining traction, especially in oncology, neurology, and toxicity testing reducing drug attrition rates and offering more physiologically relevant data than 2D cultures.

The industry is facing price volatility and procurement delays, especially for high-grade FBS, recombinant proteins, and lab plastics, urging firms to diversify suppliers and invest in supply chain resilience. Companies are responding by diversifying suppliers, expanding regional manufacturing, investing in in-house production, and using AI-based forecasting to improve resilience and reduce dependency on global supply chains.

Key challenges include scaling adherent cells, ensuring batch-to-batch consistency, and adapting to closed, automated systems—especially for companies moving from research-grade reagents to clinical-grade platforms. To address this, they’re adopting closed, automated bioreactor systems, using pre-validated GMP media, and partnering with CDMOs for tech transfer and regulatory support.

Governments in China, Singapore, and India have launched biotech funds and incentives—e.g., China’s 14th Five-Year Plan, which includes $10B+ allocated to biomanufacturing infrastructure, boosting local cell culture production. Similarly, initiatives like India’s Biotechnology Industry Research Assistance Council (BIRAC) are accelerating biotech capacity, directly boosting media and reagent demand.

Starting 2025, the US plans to impose 25% tariffs on certain Chinese-origin biologics and biomanufacturing equipment, including lab-grade media, reagents, plastics, and filtration units likely leading to 5–15% cost inflation for US-based manufacturers relying on Chinese imports. Firms are diversifying suppliers, localizing production of media and consumables, and entering strategic partnerships with domestic and EU-based vendors to secure critical raw materials and maintain compliance.

Yes. Africa, LATAM, and parts of Southeast Asia face challenges accessing high-quality media and reagents due to import dependency, limited local suppliers, and regulatory bottlenecks highlighting a need for regional manufacturing hubs. To overcome this, companies and governments are investing in local production facilities, forming regional supply partnerships to improve access and self-sufficiency.

Companies are launching custom media formulations, 3D culture platforms, and closed single-use bioreactor systems. Recent launches such as Thermo Fisher’s Gibco CTS media line, Nucleus Biologics’s NB-KUL DF, a DMSO-free, chemically defined cryomedia target consistent performance in cell therapy and protein expression, respectively.

In the past 2 years, leading players have made multiple acquisitions (e.g., Sartorius acquiring Albumedix, Thermo Fisher acquiring PeproTech) and expanded GMP-grade media facilities to strengthen biologics and cell therapy manufacturing offerings. In 2024, Fujifilm invested $1.2 billion in its large-scale cell culture CDMO facility in North Carolina